{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:30:58Z","timestamp":1794774658258,"version":"4.9.1"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA009592"],"award-info":[{"award-number":["T32CA009592"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["2T32CA009582-32"],"award-info":[{"award-number":["2T32CA009582-32"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA217987"],"award-info":[{"award-number":["R01CA217987"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA214494"],"award-info":[{"award-number":["CA214494"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA211695-01A1"],"award-info":[{"award-number":["R01CA211695-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5 R01 CA218526-04"],"award-info":[{"award-number":["5 R01 CA218526-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["131356-RSG-17-160-01-CSM"],"award-info":[{"award-number":["131356-RSG-17-160-01-CSM"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cribriform prostate cancer, found in both invasive cribriform carcinoma (ICC) and intraductal carcinoma (IDC), is an aggressive histological subtype that is associated with progression to lethal disease. To delineate the molecular and cellular underpinnings of ICC\/IDC aggressiveness, this study examines paired ICC\/IDC and benign prostate surgical samples by single-cell RNA-sequencing, TCR sequencing, and histology. ICC\/IDC cancer cells express genes associated with metastasis and targets with potential for therapeutic intervention. Pathway analyses and ligand\/receptor status model cellular interactions among ICC\/IDC and the tumor microenvironment (TME) including JAG1\/NOTCH. The ICC\/IDC TME is hallmarked by increased angiogenesis and immunosuppressive fibroblasts (\n                    <jats:italic>CTHRC1<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>+<\/jats:italic>\n                    <\/jats:sup>\n                    <jats:italic>ASPN<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>+<\/jats:italic>\n                    <\/jats:sup>\n                    <jats:italic>FAP<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>+<\/jats:italic>\n                    <\/jats:sup>\n                    <jats:italic>ENG<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>+<\/jats:italic>\n                    <\/jats:sup>\n                    ) along with fewer T cells, elevated T cell dysfunction, and increased\n                    <jats:italic>C1QB<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>+<\/jats:italic>\n                    <\/jats:sup>\n                    <jats:italic>TREM2<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>+<\/jats:italic>\n                    <\/jats:sup>\n                    <jats:italic>APOE<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    -M2 macrophages. These findings support that cancer cell intrinsic pathways and a complex immunosuppressive TME contribute to the aggressive phenotype of ICC\/IDC. These data highlight potential therapeutic opportunities to restore immune signaling in patients with ICC\/IDC that may afford better outcomes.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-33780-1","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T06:02:53Z","timestamp":1665640973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease"],"prefix":"10.1038","volume":"13","author":[{"given":"Hong Yuen","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8951-9295","authenticated-orcid":false,"given":"Quanhu","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda B.","family":"Hesterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Croessmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda L.","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khem","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgen","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3140-1953","authenticated-orcid":false,"given":"Adam X.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry R.","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Duke","family":"Herrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy N.","family":"Luckenbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Barocas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8434-4561","authenticated-orcid":false,"given":"Young J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0326-3207","authenticated-orcid":false,"given":"Giovanna A.","family":"Giannico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4106-3396","authenticated-orcid":false,"given":"Jeffrey C.","family":"Rathmell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0745-2160","authenticated-orcid":false,"given":"Jennifer B.","family":"Gordetsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1487-9282","authenticated-orcid":false,"given":"Paula J.","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"33780_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/PAS.0000000000000820","volume":"41","author":"JI Epstein","year":"2017","unstructured":"Epstein, J. I., Amin, M. B., Reuter, V. E. & Humphrey, P. A. Contemporary gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 international society of urological pathology (isup) consensus conference on gleason grading of prostatic carcinoma. Am. J. Surg. Pathol. 41, e1\u2013e7 (2017).","journal-title":"Am. J. Surg. Pathol."},{"key":"33780_CR2","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1038\/modpathol.2017.133","volume":"31","author":"JI Epstein","year":"2018","unstructured":"Epstein, J. I. Prostate cancer grading: a decade after the 2005 modified system. Mod. Pathol. 31, S47\u2013S63 (2018).","journal-title":"Mod. Pathol."},{"key":"33780_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1464-410X.2012.11611.x","volume":"111","author":"PM Pierorazio","year":"2013","unstructured":"Pierorazio, P. M., Walsh, P. C., Partin, A. W. & Epstein, J. I. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 111, 753\u2013760 (2013).","journal-title":"BJU Int."},{"key":"33780_CR4","first-page":"125","volume":"50","author":"DF Gleason","year":"1966","unstructured":"Gleason, D. F. Classification of prostatic carcinomas. Cancer Chemother. Rep. 50, 125\u2013128 (1966).","journal-title":"Cancer Chemother. Rep."},{"key":"33780_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.humpath.2020.02.004","volume":"98","author":"MC Haffner","year":"2020","unstructured":"Haffner, M. C., Salles, D. C., Gao, G. & Epstein, J. I. Gleason pattern 4 with cribriform morphology on biopsy is associated with adverse clinicopathological findings in a prospective radical prostatectomy cohort. Hum. Pathol. 98, 74\u201380 (2020).","journal-title":"Hum. Pathol."},{"key":"33780_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41379-018-0157-9","volume":"32","author":"E Hollemans","year":"2019","unstructured":"Hollemans, E. et al. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. Mod. Pathol. 32, 139\u2013146 (2019).","journal-title":"Mod. Pathol."},{"key":"33780_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/modpathol.2014.116","volume":"28","author":"CF Kweldam","year":"2015","unstructured":"Kweldam, C. F. et al. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod. Pathol. 28, 457\u2013464 (2015).","journal-title":"Mod. Pathol."},{"key":"33780_CR8","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1097\/PAS.0000000000000691","volume":"40","author":"B Choy","year":"2016","unstructured":"Choy, B. et al. Prognostic significance of percentage and architectural types of contemporary gleason pattern 4 prostate cancer in radical prostatectomy. Am. J. Surg. Pathol. 40, 1400\u20131406 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"33780_CR9","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1097\/PAS.0000000000000736","volume":"40","author":"JK McKenney","year":"2016","unstructured":"McKenney, J. K. et al. Histologic grading of prostatic adenocarcinoma can be further optimized: analysis of the relative prognostic strength of individual architectural patterns in 1275 patients from the canary retrospective cohort. Am. J. Surg. Pathol. 40, 1439\u20131456 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"33780_CR10","doi-asserted-by":"publisher","unstructured":"Hesterberg, A. B., Gordetsky, J. B. & Hurley, P. J. Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations. Urology https:\/\/doi.org\/10.1016\/j.urology.2021.05.028 (2021).","DOI":"10.1016\/j.urology.2021.05.028"},{"key":"33780_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.21037\/tau.2017.12.33","volume":"7","author":"CF Kweldam","year":"2018","unstructured":"Kweldam, C. F., van der Kwast, T. & van Leenders, G. J. On cribriform prostate cancer. Transl. Androl. Urol. 7, 145\u2013154 (2018).","journal-title":"Transl. Androl. Urol."},{"key":"33780_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5858\/arpa.2020-0015-RA","volume":"145","author":"JI Epstein","year":"2021","unstructured":"Epstein, J. I. et al. The 2019 genitourinary pathology society (GUPS) white paper on contemporary grading of prostate cancer. Arch. Pathol. Lab Med. 145, 461\u2013493 (2021).","journal-title":"Arch. Pathol. Lab Med"},{"key":"33780_CR13","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"G van Leenders","year":"2020","unstructured":"van Leenders, G. et al. The 2019 international society of urological pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am. J. Surg. Pathol. 44, e87\u2013e99 (2020).","journal-title":"Am. J. Surg. Pathol."},{"key":"33780_CR14","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.ejca.2014.03.009","volume":"50","author":"D Trudel","year":"2014","unstructured":"Trudel, D. et al. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. Eur. J. Cancer 50, 1610\u20131616 (2014).","journal-title":"Eur. J. Cancer"},{"key":"33780_CR15","doi-asserted-by":"publisher","unstructured":"Hollemans, E. et al. Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients. Mod. Pathol. Urology https:\/\/doi.org\/10.1038\/s41379-020-0625-x (2020).","DOI":"10.1038\/s41379-020-0625-x"},{"key":"33780_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/1541-7786.MCR-18-0440","volume":"17","author":"H Elfandy","year":"2019","unstructured":"Elfandy, H. et al. Genetic and epigenetic determinants of aggressiveness in cribriform carcinoma of the prostate. Mol. Cancer Res. 17, 446\u2013456 (2019).","journal-title":"Mol. Cancer Res."},{"key":"33780_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/JU.0000000000000526","volume":"203","author":"KJ Ericson","year":"2020","unstructured":"Ericson, K. J. et al. Diagnostic accuracy of prostate biopsy for detecting cribriform gleason pattern 4 carcinoma and intraductal carcinoma in paired radical prostatectomy specimens: implications for active surveillance. J. Urol. 203, 311\u2013319 (2020).","journal-title":"J. Urol."},{"key":"33780_CR18","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ejca.2020.09.016","volume":"148","author":"MR Downes","year":"2021","unstructured":"Downes, M. R., Xu, B. & van der Kwast, T. H. Cribriform architecture prostatic adenocarcinoma in needle biopsies is a strong independent predictor for lymph node metastases in radical prostatectomy. Eur. J. Cancer 148, 432\u2013439 (2021).","journal-title":"Eur. J. Cancer"},{"key":"33780_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3976-z","volume":"18","author":"R Bottcher","year":"2018","unstructured":"Bottcher, R. et al. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer 18, 8 (2018).","journal-title":"BMC Cancer"},{"key":"33780_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.eururo.2017.04.034","volume":"72","author":"MLK Chua","year":"2017","unstructured":"Chua, M. L. K. et al. A prostate cancer \u201cnimbosus\u201d: genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies. Eur. Urol. 72, 665\u2013674 (2017).","journal-title":"Eur. Urol."},{"key":"33780_CR21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.eururo.2014.08.007","volume":"67","author":"GP Risbridger","year":"2015","unstructured":"Risbridger, G. P. et al. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur. Urol. 67, 496\u2013503 (2015).","journal-title":"Eur. Urol."},{"key":"33780_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13671","volume":"8","author":"RA Taylor","year":"2017","unstructured":"Taylor, R. A. et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nat. Commun. 8, 13671 (2017).","journal-title":"Nat. Commun."},{"key":"33780_CR23","doi-asserted-by":"publisher","unstructured":"Schweizer, M. T. et al. Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations. JCO Precis. Oncol. 3 https:\/\/doi.org\/10.1200\/PO.18.00327 (2019).","DOI":"10.1200\/PO.18.00327"},{"key":"33780_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejca.2021.01.027","volume":"147","author":"R Lozano","year":"2021","unstructured":"Lozano, R. et al. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. Eur. J. Cancer 147, 74\u201383 (2021).","journal-title":"Eur. J. Cancer"},{"key":"33780_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/PAS.0000000000000348","volume":"39","author":"CL Morais","year":"2015","unstructured":"Morais, C. L. et al. Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy. Am. J. Surg. Pathol. 39, 169\u2013178 (2015).","journal-title":"Am. J. Surg. Pathol."},{"key":"33780_CR26","doi-asserted-by":"publisher","unstructured":"Spieker, A. J. et al. PTEN Expression and Morphologic Patterns in Prostatic Adenocarcinoma. Histopathology https:\/\/doi.org\/10.1111\/his.14531 (2021).","DOI":"10.1111\/his.14531"},{"key":"33780_CR27","doi-asserted-by":"publisher","first-page":"104400","DOI":"10.1016\/j.yexmp.2020.104400","volume":"114","author":"GQ Xiao","year":"2020","unstructured":"Xiao, G. Q., Nguyen, E., Unger, P. D. & Sherrod, A. E. Comparative expression of immunohistochemical biomarkers in cribriform and pattern 4 non-cribriform prostatic adenocarcinoma. Exp. Mol. Pathol. 114, 104400 (2020).","journal-title":"Exp. Mol. Pathol."},{"key":"33780_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03455-8","volume":"12","author":"K Huang","year":"2021","unstructured":"Huang, K. & Tang, Y. SChLAP1 promotes prostate cancer development through interacting with EZH2 to mediate promoter methylation modification of multiple miRNAs of chromosome 5 with a DNMT3a-feedback loop. Cell Death Dis. 12, 188 (2021).","journal-title":"Cell Death Dis."},{"key":"33780_CR29","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.neo.2021.05.012","volume":"23","author":"SG Kidd","year":"2021","unstructured":"Kidd, S. G. et al. High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity. Neoplasia 23, 634\u2013641 (2021).","journal-title":"Neoplasia"},{"key":"33780_CR30","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/ng.2771","volume":"45","author":"JR Prensner","year":"2013","unstructured":"Prensner, J. R. et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI\/SNF complex. Nat. Genet. 45, 1392\u20131398 (2013).","journal-title":"Nat. Genet."},{"key":"33780_CR31","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/S1470-2045(14)71113-1","volume":"15","author":"JR Prensner","year":"2014","unstructured":"Prensner, J. R. et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 15, 1469\u20131480 (2014).","journal-title":"Lancet Oncol."},{"key":"33780_CR32","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41379-019-0221-0","volume":"32","author":"EI Verhoef","year":"2019","unstructured":"Verhoef, E. I. et al. Three-dimensional analysis reveals two major architectural subgroups of prostate cancer growth patterns. Mod. Pathol. 32, 1032\u20131041 (2019).","journal-title":"Mod. Pathol."},{"key":"33780_CR33","doi-asserted-by":"publisher","unstructured":"Hesterberg, A. B. et al. A distinct repertoire of cancer-associated fibroblasts is enriched in cribriform prostate cancer. J. Pathol. Clin. Res.https:\/\/doi.org\/10.1002\/cjp2.205 (2021).","DOI":"10.1002\/cjp2.205"},{"key":"33780_CR34","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1126\/science.1195300","volume":"330","author":"M Kraman","year":"2010","unstructured":"Kraman, M. et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330, 827\u2013830 (2010).","journal-title":"Science"},{"key":"33780_CR35","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212\u201320217 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"33780_CR36","doi-asserted-by":"publisher","unstructured":"Crowley, L. et al. A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors. Elife 9 https:\/\/doi.org\/10.7554\/eLife.59465 (2020).","DOI":"10.7554\/eLife.59465"},{"key":"33780_CR37","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s00259-019-04320-9","volume":"46","author":"J Gao","year":"2019","unstructured":"Gao, J. et al. Diagnostic performance of (68)Ga-PSMA PET\/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections. Eur. J. Nucl. Med. Mol. Imaging 46, 1531\u20131541 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"33780_CR38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.eururo.2015.12.003","volume":"70","author":"R Mehra","year":"2016","unstructured":"Mehra, R. et al. Overexpression of the long non-coding RNA SChLAP1 independently predicts lethal prostate cancer. Eur. Urol. 70, 549\u2013552 (2016).","journal-title":"Eur. Urol."},{"key":"33780_CR39","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.neo.2014.11.006","volume":"16","author":"R Mehra","year":"2014","unstructured":"Mehra, R. et al. A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. Neoplasia 16, 1121\u20131127 (2014).","journal-title":"Neoplasia"},{"key":"33780_CR40","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. & Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81\u201385 (1997).","journal-title":"Clin. Cancer Res"},{"key":"33780_CR41","doi-asserted-by":"publisher","unstructured":"Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2107322 (2021).","DOI":"10.1056\/NEJMoa2107322"},{"key":"33780_CR42","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman, M. S. et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397, 797\u2013804 (2021).","journal-title":"Lancet"},{"key":"33780_CR43","first-page":"5975","volume":"59","author":"MJ Bussemakers","year":"1999","unstructured":"Bussemakers, M. J. et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 59, 5975\u20135979 (1999).","journal-title":"Cancer Res"},{"key":"33780_CR44","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.18632\/oncotarget.27284","volume":"10","author":"AEG Lemos","year":"2019","unstructured":"Lemos, A. E. G., Matos, A. D. R., Ferreira, L. B. & Gimba, E. R. P. The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer. Oncotarget 10, 6589\u20136603 (2019).","journal-title":"Oncotarget"},{"key":"33780_CR45","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/JU.0000000000000193","volume":"202","author":"MI Echevarria","year":"2019","unstructured":"Echevarria, M. I. et al. African american specific gene panel predictive of poor prostate cancer outcome. J. Urol. 202, 247\u2013255 (2019).","journal-title":"J. Urol."},{"key":"33780_CR46","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/pcan.2016.49","volume":"20","author":"B Benzon","year":"2017","unstructured":"Benzon, B. et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis. 20, 28\u201335 (2017).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"33780_CR47","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/onc.2016.232","volume":"36","author":"Q Su","year":"2017","unstructured":"Su, Q. et al. Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer. Oncogene 36, 618\u2013627 (2017).","journal-title":"Oncogene"},{"key":"33780_CR48","doi-asserted-by":"publisher","first-page":"6854","DOI":"10.1158\/0008-5472.CAN-04-2500","volume":"64","author":"S Santagata","year":"2004","unstructured":"Santagata, S. et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 64, 6854\u20136857 (2004).","journal-title":"Cancer Res"},{"key":"33780_CR49","first-page":"368","volume":"5","author":"H Zhu","year":"2013","unstructured":"Zhu, H., Zhou, X., Redfield, S., Lewin, J. & Miele, L. Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. Am. J. Transl. Res. 5, 368\u2013378 (2013).","journal-title":"Am. J. Transl. Res."},{"key":"33780_CR50","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1016\/j.celrep.2018.11.086","volume":"25","author":"GH Henry","year":"2018","unstructured":"Henry, G. H. et al. A cellular anatomy of the normal adult human prostate and prostatic urethra. Cell Rep. 25, 3530\u20133542 e3535. (2018).","journal-title":"Cell Rep."},{"key":"33780_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27322-4","volume":"13","author":"H Song","year":"2022","unstructured":"Song, H. et al. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat. Commun. 13, 141 (2022).","journal-title":"Nat. Commun."},{"key":"33780_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2019.12.001","volume":"37","author":"J Goveia","year":"2020","unstructured":"Goveia, J. et al. An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates. Cancer Cell 37, 21\u201336.e13 (2020).","journal-title":"Cancer Cell"},{"key":"33780_CR53","first-page":"3990","volume":"11","author":"RB Shah","year":"2021","unstructured":"Shah, R. B. et al. Diagnosis of \u201ccribriform\u201d prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. Am. J. Cancer Res. 11, 3990\u20134001 (2021).","journal-title":"Am. J. Cancer Res"},{"key":"33780_CR54","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/jnci\/djy234","volume":"111","author":"C Strell","year":"2019","unstructured":"Strell, C. et al. Impact of epithelial-stromal interactions on peritumoral fibroblasts in ductal carcinoma in situ. J. Natl Cancer Inst. 111, 983\u2013995 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"33780_CR55","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai, E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20, 174\u2013186 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"33780_CR56","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102\u20131123 (2019).","journal-title":"Cancer Discov."},{"key":"33780_CR57","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D Ohlund","year":"2017","unstructured":"Ohlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579\u2013596 (2017).","journal-title":"J. Exp. Med"},{"key":"33780_CR58","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","volume":"10","author":"Y Kieffer","year":"2020","unstructured":"Kieffer, Y. et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 10, 1330\u20131351 (2020).","journal-title":"Cancer Discov."},{"key":"33780_CR59","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez, C. X. et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15(\u2009+\u2009) myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 10, 232\u2013253 (2020).","journal-title":"Cancer Discov."},{"key":"33780_CR60","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/1078-0432.CCR-21-3570","volume":"28","author":"A Obradovic","year":"2022","unstructured":"Obradovic, A. et al. Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer. Clin. Cancer Res. 28, 2094\u20132109 (2022).","journal-title":"Clin. Cancer Res."},{"key":"33780_CR61","doi-asserted-by":"publisher","unstructured":"Joseph, D. B. et al. Single-cell analysis of mouse and human prostate reveals novel fibroblasts with specialized distribution and microenvironment interactions. J. Pathol. https:\/\/doi.org\/10.1002\/path.5751 (2021).","DOI":"10.1002\/path.5751"},{"key":"33780_CR62","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.bbrc.2017.03.021","volume":"486","author":"WD Ni","year":"2017","unstructured":"Ni, W. D. et al. Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer. Biochem Biophys. Res. Commun. 486, 607\u2013612 (2017).","journal-title":"Biochem Biophys. Res. Commun."},{"key":"33780_CR63","first-page":"21","volume":"1775","author":"K Pardali","year":"2007","unstructured":"Pardali, K. & Moustakas, A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys. Acta. 1775, 21\u201362 (2007).","journal-title":"Biochim Biophys. Acta"},{"key":"33780_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14622-3","volume":"7","author":"E Sandsmark","year":"2017","unstructured":"Sandsmark, E. et al. SFRP4 gene expression is increased in aggressive prostate cancer. Sci. Rep. 7, 14276 (2017).","journal-title":"Sci. Rep."},{"key":"33780_CR65","doi-asserted-by":"publisher","unstructured":"Gwak, J. et al. SFMBT2-mediated infiltration of preadipocytes and TAMs in prostate cancer. Cancers (Basel) 12 https:\/\/doi.org\/10.3390\/cancers12092718 (2020).","DOI":"10.3390\/cancers12092718"},{"key":"33780_CR66","first-page":"4244","volume":"20","author":"Q Zhou","year":"2019","unstructured":"Zhou, Q. et al. CTHRC1 and PD1\/PDL1 expression predicts tumor recurrence in prostate cancer. Mol. Med. Rep. 20, 4244\u20134252 (2019).","journal-title":"Mol. Med. Rep."},{"key":"33780_CR67","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1038\/s41388-021-01827-0","volume":"40","author":"XL Zhang","year":"2021","unstructured":"Zhang, X. L. et al. CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-beta receptors in colorectal cancer. Oncogene 40, 3959\u20133973 (2021).","journal-title":"Oncogene"},{"key":"33780_CR68","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1158\/0008-5472.CAN-18-2931","volume":"79","author":"RM Hughes","year":"2019","unstructured":"Hughes, R. M. et al. Asporin restricts mesenchymal stromal cell differentiation, alters the tumor microenvironment, and drives metastatic progression. Cancer Res. 79, 3636\u20133650 (2019).","journal-title":"Cancer Res"},{"key":"33780_CR69","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1158\/1078-0432.CCR-15-0256","volume":"22","author":"PJ Hurley","year":"2016","unstructured":"Hurley, P. J. et al. Germline variants in asporin vary by race, modulate the tumor microenvironment, and are differentially associated with metastatic prostate cancer. Clin. Cancer Res. 22, 448\u2013458 (2016).","journal-title":"Clin. Cancer Res"},{"key":"33780_CR70","doi-asserted-by":"publisher","unstructured":"Fitzgerald, A. A. & Weiner, L. M. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. https:\/\/doi.org\/10.1007\/s10555-020-09909-3 (2020).","DOI":"10.1007\/s10555-020-09909-3"},{"key":"33780_CR71","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.21873\/anticanres.14088","volume":"40","author":"AC Vidal","year":"2020","unstructured":"Vidal, A. C. et al. Soluble endoglin (sCD105) as a novel biomarker for detecting aggressive prostate cancer. Anticancer Res. 40, 1459\u20131462 (2020).","journal-title":"Anticancer Res"},{"key":"33780_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/ERC-19-0370","volume":"27","author":"VR Placencio-Hickok","year":"2020","unstructured":"Placencio-Hickok, V. R. et al. Soluble CD105 is prognostic of disease recurrence in prostate cancer patients. Endocr. Relat. Cancer 27, 1\u20139 (2020).","journal-title":"Endocr. Relat. Cancer"},{"key":"33780_CR73","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41388-018-0461-3","volume":"38","author":"M Kato","year":"2019","unstructured":"Kato, M. et al. Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner. Oncogene 38, 716\u2013730 (2019).","journal-title":"Oncogene"},{"key":"33780_CR74","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400\u2013416 (2018).","journal-title":"Cell"},{"key":"33780_CR75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11\u201322 (2010).","journal-title":"Cancer Cell"},{"key":"33780_CR76","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","volume":"176","author":"H Li","year":"2019","unstructured":"Li, H. et al. Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell 176, 775\u2013789 (2019).","journal-title":"Cell"},{"key":"33780_CR77","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8(\u2009+\u2009) T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218\u2013232 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"33780_CR78","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"33780_CR79","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41591-019-0734-6","volume":"26","author":"BP Fairfax","year":"2020","unstructured":"Fairfax, B. P. et al. Peripheral CD8(\u2009+\u2009) T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. Nat. Med 26, 193\u2013199 (2020).","journal-title":"Nat. Med"},{"key":"33780_CR80","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1016\/j.cell.2021.04.038","volume":"184","author":"A Obradovic","year":"2021","unstructured":"Obradovic, A. et al. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. 184, 2988\u20133005.e2916. (2021).","journal-title":"Cell"},{"key":"33780_CR81","doi-asserted-by":"publisher","first-page":"128965","DOI":"10.1155\/2012\/128965","volume":"2012","author":"BW Tse","year":"2012","unstructured":"Tse, B. W., Scott, K. F. & Russell, P. J. Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology. Prostate Cancer 2012, 128965 (2012).","journal-title":"Prostate Cancer"},{"key":"33780_CR82","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi, K. & Karin, M. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat. Rev. Immunol. 18, 309\u2013324 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"33780_CR83","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-13-2543","volume":"74","author":"R Jin","year":"2014","unstructured":"Jin, R. et al. NF-kappaB gene signature predicts prostate cancer progression. Cancer Res. 74, 2763\u20132772 (2014).","journal-title":"Cancer Res"},{"key":"33780_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1159","volume":"2","author":"VK Rajasekhar","year":"2011","unstructured":"Rajasekhar, V. K., Studer, L., Gerald, W., Socci, N. D. & Scher, H. I. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat. Commun. 2, 162 (2011).","journal-title":"Nat. Commun."},{"key":"33780_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08593-y","volume":"21","author":"EL Imada","year":"2021","unstructured":"Imada, E. L. et al. Transcriptional landscape of PTEN loss in primary prostate cancer. BMC Cancer 21, 856 (2021).","journal-title":"BMC Cancer"},{"key":"33780_CR86","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/(SICI)1097-0045(20000501)43:2<150::AID-PROS10>3.0.CO;2-B","volume":"43","author":"RL Sokoloff","year":"2000","unstructured":"Sokoloff, R. L., Norton, K. C., Gasior, C. L., Marker, K. M. & Grauer, L. S. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 43, 150\u2013157 (2000).","journal-title":"Prostate"},{"key":"33780_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21615-4","volume":"12","author":"L Brady","year":"2021","unstructured":"Brady, L. et al. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat. Commun. 12, 1426 (2021).","journal-title":"Nat. Commun."},{"key":"33780_CR88","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ijc.23871","volume":"124","author":"A Kennedy","year":"2009","unstructured":"Kennedy, A., Dong, H., Chen, D. & Chen, W. T. Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells. Int J. Cancer 124, 27\u201335 (2009).","journal-title":"Int J. Cancer"},{"key":"33780_CR89","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","volume":"18","author":"ST Paijens","year":"2021","unstructured":"Paijens, S. T., Vledder, A., de Bruyn, M. & Nijman, H. W. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol. Immunol. 18, 842\u2013859 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"33780_CR90","doi-asserted-by":"publisher","unstructured":"Subudhi, S. K. et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 12 https:\/\/doi.org\/10.1126\/scitranslmed.aaz3577 (2020).","DOI":"10.1126\/scitranslmed.aaz3577"},{"key":"33780_CR91","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"33780_CR92","doi-asserted-by":"publisher","unstructured":"Sena, L. A., Denmeade, S. R. & Antonarakis, E. S. Targeting the spectrum of immune checkpoints in prostate cancer. Expert Rev. Clin. Pharmacol. 1\u201314 https:\/\/doi.org\/10.1080\/17512433.2021.1949287 (2021).","DOI":"10.1080\/17512433.2021.1949287"},{"key":"33780_CR93","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1158\/1078-0432.CCR-19-2931","volume":"26","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant pd-1 blockade in resectable non-small cell lung cancer. Clin. Cancer Res. 26, 1327\u20131337 (2020).","journal-title":"Clin. Cancer Res"},{"key":"33780_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06653-9","volume":"9","author":"CA Egelston","year":"2018","unstructured":"Egelston, C. A. et al. Human breast tumor-infiltrating CD8(\u2009+\u2009) T cells retain polyfunctionality despite PD-1 expression. Nat. Commun. 9, 4297 (2018).","journal-title":"Nat. Commun."},{"key":"33780_CR95","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8(\u2009+\u2009) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"33780_CR96","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/pros.23742","volume":"79","author":"A Erlandsson","year":"2019","unstructured":"Erlandsson, A. et al. M2 macrophages and regulatory T cells in lethal prostate cancer. Prostate 79, 363\u2013369 (2019).","journal-title":"Prostate"},{"key":"33780_CR97","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1038\/onc.2013.191","volume":"33","author":"G Comito","year":"2014","unstructured":"Comito, G. et al. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene 33, 2423\u20132431 (2014).","journal-title":"Oncogene"},{"key":"33780_CR98","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700\u2013712 (2014).","journal-title":"Lancet Oncol."},{"key":"33780_CR99","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"33780_CR100","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein, J. I. et al. The 2014 international society of urological pathology (isup) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 40, 244\u2013252 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"33780_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049","volume":"8","author":"GX Zheng","year":"2017","unstructured":"Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).","journal-title":"Nat. Commun."},{"key":"33780_CR102","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1093\/bioinformatics\/btz601","volume":"35","author":"Q Liu","year":"2019","unstructured":"Liu, Q. et al. scRNABatchQC: multi-samples quality control for single cell RNA-seq data. Bioinformatics 35, 5306\u20135308 (2019).","journal-title":"Bioinformatics"},{"key":"33780_CR103","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888\u20131902.e1821 (2019).","journal-title":"Cell"},{"key":"33780_CR104","doi-asserted-by":"publisher","unstructured":"Franzen, O., Gan, L. M. & Bjorkegren, J. L. M. PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. Database (Oxford) https:\/\/doi.org\/10.1093\/database\/baz046 (2019).","DOI":"10.1093\/database\/baz046"},{"key":"33780_CR105","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"33780_CR106","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"33780_CR107","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0560-6","volume":"16","author":"M Lizio","year":"2015","unstructured":"Lizio, M. et al. Gateways to the FANTOM5 promoter level mammalian expression atlas. Genome Biol. 16, 22 (2015).","journal-title":"Genome Biol."},{"key":"33780_CR108","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nbt.2859","volume":"32","author":"C Trapnell","year":"2014","unstructured":"Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381\u2013386 (2014).","journal-title":"Nat. Biotechnol."},{"key":"33780_CR109","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nmeth.4150","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu, X. et al. Single-cell mRNA quantification and differential analysis with Census. Nat. Methods 14, 309\u2013315 (2017).","journal-title":"Nat. Methods"},{"key":"33780_CR110","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","volume":"26","author":"D Mahalingam","year":"2020","unstructured":"Mahalingam, D. et al. Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a phase IB study. Clin. Cancer Res. 26, 71\u201381 (2020).","journal-title":"Clin. Cancer Res"},{"key":"33780_CR111","doi-asserted-by":"publisher","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1 https:\/\/doi.org\/10.1126\/scisignal.2004088 (2013).","DOI":"10.1126\/scisignal.2004088"},{"key":"33780_CR112","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"33780_CR113","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495\u2013502 (2015).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33780-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33780-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33780-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T07:06:00Z","timestamp":1665644760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33780-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["33780"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-33780-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"assertion":[{"value":"13 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.J.H., B.H.P., Y.J.K., and J.R. declare the following potential competing interests. P.J.H. receives royalties from Horizon Discovery, LTD for the generation of targeted cell lines under a licensing agreement between Horizon Discovery, LTD and Johns Hopkins University. B.H.P. is a paid consultant for Jackson Labs, EQRx, Hologic, Sermonix, is a paid scientific advisory board member for Celcuity Inc., and receives research funding from GE Healthcare, Lilly, and Pfizer. Under separate licensing agreements between Horizon Discovery, LTD and The Johns Hopkins University, B.H.P. is entitled to a share of royalties received by the University on sales of products. The terms of this arrangement are being managed by Johns Hopkins University in accordance with its conflict-of-interest policies. Y.J.K. is a full-time stockholding employee of Regeneron with stock options. J.R. is a founder, scientific advisory board member, and stockholder of Sitryx Therapeutics, a scientific advisory board member and stockholder of Caribou Biosciences, a member of the scientific advisory board of Nirogy Therapeutics, has consulted for Merck, Pfizer, and Mitobridge within the past three years, and has received research support from Incyte Corp., Calithera Biosciences, and Tempest Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6036"}}